<DOC>
	<DOC>NCT02238158</DOC>
	<brief_summary>To obtain further information on the tolerability and efficacy of Atrovent® inhalets in long term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Primarily patients of both gender, older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion • Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® Inhalets</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>